Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

Published 2016 View Full Article

Authors

Keywords

Alirocumab, Ezetimibe, Low-density lipoprotein cholesterol, Monoclonal antibody, PCSK9, Rosuvastatin

Journal

ATHEROSCLEROSIS

Volume 244, Issue -, Pages 138-146

Publisher

Elsevier BV

Online

2015-11-14

DOI

10.1016/j.atherosclerosis.2015.11.010

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started